NCT00098280View on ClinicalTrials.gov

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

February 28, 2006

Conditions
Hemoglobinuria, Paroxysmal
Interventions
DRUG

Eculizumab

Trial Locations (1)

20892

National Heart, Lung and Blood Institute (NHLBI), Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00098280 - Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter | Biotech Hunter